Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.
Avastin® (bevacizumab) is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF. Normal cells make VEGF, but some cancer cells make too much VEGF. Blocking VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors.
Unlike chemotherapy that attacks the cancer cells, the purpose of Avastin is to block the blood supply that feeds the tumor. This can stop the tumor from growing.1
In Bangladesh Avastin is approved for the following indications.2
Avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.
Avastin in combination with standard cytotoxic chemotherapy is indicated for first-line treatment of patients with locally recurrent or metastatic breast cancer.
Avastin in combination with taxanes, capecitabine or gemcitabine, is indicated for the treatment of patients with metastatic breast cancer after failure of first-line cytotoxic chemotherapy.
Avastin, in addition to platinum-based chemotherapy, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer.
Avastin, in combination with erlotinib, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.
Avastin in combination with interferon alfa-2a is indicated for first-line treatment of patients with advanced and/or metastatic renal cell cancer.
Avastin in combination with radiotherapy and temozolomide is indicated for the treatment of adult patients with newly diagnosed glioblastoma.
Avastin, as a single agent, or in combination with irinotecan, is indicated for the treatment of patients with glioblastoma after relapse or disease progression.
Avastin, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Avastin, in combination with carboplatin and gemcitabine is indicated for the treatment of patients with recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Avastin in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens.
Avastin in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for the treatment of persistent, recurrent, or metastatic carcinoma of the cervix.
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh Avastin is available as
Vial 400 mg/16 ml
Vial 100 mg/4 ml
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
References:
How is Avastin designed to work? [Internet; cited 2018, November 08]. Retrieved from
Avastin-Product-Information-BD-Ro-487-6646-October-2022
This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.